Products
PROMUS® Everolimus-Eluting Coronary Stent System
Excellent Angiographic and Clinical Results1
The SPIRIT Clinical Trial Program demonstrates the safety and efficacy of the XIENCE V® (PROMUS) Stent.
Consistently low late loss and TLR...
...with long-term safety data.
1 SPIRIT sponsored by Abbott. SPIRIT FIRST 6-month data: Serruys PW, Ong A, Piek J. A randomized comparison of a durable polymer everolimus-eluting stent with a bare-metal coronary stent: the SPIRIT FIRST Trial. EuroIntervention. 2005;1:58-65. SPIRIT FIRST 4-Year Results Presentation, PCR 2008; presented by Dr. Stephen Windecker. SPIRIT II 6-Month Results Presentation, ESC 2006; presented by Dr. Patrick Serruys. SPIRIT II 2-Year Results Presentation, ACC 2008; presented by Dr. Patrick Serruys. SPIRIT II 4-Year Results Presentation, ACC 2010; presented by Dr. Yoshinobu Onuma. SPIRIT III 9-Month Results Presentation, ACC 2007; presented by Dr. Gregg W. Stone. SPIRIT III 2-Year Results Presentation, PCR 2008; presented by Dr. Gregg W. Stone.
Prior to use, please see the complete "Directions for Use" at www.bostonscientific.com/promus for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events and Operator's Instructions. PROMUS Stent is a private-labeled XIENCE V® Everolimus Eluting Coronary Stent System manufactured by Abbot and distributed by Boston Scientific Corporation. XIENCE V is a trademark of Abbott Laboratories group of companies.
